Read by QxMD icon Read

Her2 negative breast cancer

Athina Kladi-Skandali, Diamantis C Sideris, Andreas Scorilas
Background Alternative splicing is a key process in carcinogenesis and, from a clinical aspect, holds great promises, as alternatively spliced variants have emerged as an untapped source of diagnostic and prognostic markers. Our aim was to assess the prognostic value of three recently recognized splice variants of the apoptosis-related gene, BCL2L12, in breast cancer (BC). Methods Total RNA was extracted from breast samples (150 BC and 80 tumor-adjacent normal tissues) and, following cDNA synthesis, a variant-specific qPCR was performed for the expressional quantification of BCL2L12 v...
October 16, 2018: Clinical Chemistry and Laboratory Medicine: CCLM
Junji Tsurutani, Yukinori Sakata, Toshiyuki Matsuoka
BACKGROUND: Few studies have examined chemotherapy-induced peripheral neuropathy (CIPN) following the administration of eribulin as first- or second-line therapy in patients with breast cancer. We therefore assessed CIPN incidence by severity and risk factors for CIPN in patients treated with eribulin for HER2-negative inoperable or recurrent breast cancer, regardless of line therapy status. METHODS: This multicenter, prospective, post-marketing observational study enrolled patients from September 2014 in Japan and followed them for 2 years...
October 15, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Hye Won Hwang, Hera Jung, Jiyeon Hyeon, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong-Han Yu, Se Kyung Lee, Misun Choi, Soo Youn Cho, Eun Yoon Cho
PURPOSE: The value of tumor-infiltrating lymphocytes (TILs) for prediction of pathologic complete response (pCR) in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) has received increasing attention. In human epidermal growth factor receptor 2 (HER2)-positive BC, advances in HER2-targeted therapy have not yet clarified the clinical implications of pre-NAC TILs. Likewise, the prognostic role of TILs for long-term survival is not well established. METHODS: Pre- and post-NAC TIL levels were evaluated in 248 pair-matched pre-NAC biopsy and post-NAC resection samples, and analyzed for predictive and prognostic significance with other clinicopathologic parameters...
October 15, 2018: Breast Cancer Research and Treatment
Bo Bae Choi, Jin Sun Lee, Kun Ho Kim
BACKGROUND: Triple-negative breast cancer (TNBC) is a breast cancer subgroup that lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Certain magnetic resonance imaging (MRI) features of TNBC might reflect the poor prognosis of TNBC. Standardized uptake value (SUV) of [18F]fluorodeoxyglucose positron emission tomography/computed tomography is 1 of predictive prognostic factors for breast cancer. The purpose of this study was to correlate MRI features of TNBC with SUVmax to determine whether MRI findings in TNBC could be helpful for predicting prognosis...
October 16, 2018: Oncology Research and Treatment
Santiago Escrivá-de-Romaní, Miriam Arumí, Esther Zamora, Meritxell Bellet
For decades, the neoadjuvant setting has provided a useful scenario for research in breast cancer. Historically, neoadjuvant clinical trials, either hormone therapy-based or chemotherapy-based, have tried to recapitulate the results of their counterpart adjuvant studies, but with smaller patient numbers, more rapid outcomes (clinical response and/or pathologic complete response (pCR)), together with additional biologic information. As for neoadjuvant chemotherapy trials, the increase in pCR rates has been recently accepted as an appropriate surrogate marker to accelerate drug approval in high-risk breast cancer patients...
August 2018: Breast Care
Cristina Pernaut, Flora Lopez, Eva Ciruelos
Neoadjuvant treatment allows us to improve surgical results and test new drugs. In recent years, there have been significant advances in the field of neoadjuvant treatment, including hormonal neoadjuvant therapy in luminal tumors, double blockade in HER2-positive tumors, and the use of platinum salts in triple-negative tumors.
August 2018: Breast Care
S Rashmi, S Kamala, S Sudha Murthy, Swapna Kotha, Y Suhas Rao, K Veeraiah Chaudhary
Aim: To determine the correlation between mammography and ultrasound features of breast cancer with molecular subtypes and to calculate the predictive value of these features. Materials and Method: This is a prospective study of consecutive patients with breast cancer presenting between January 2016 and July 2017, who underwent mammography and/or ultrasound of breast and excision of the breast mass. Patients with contralateral breast mass, metastases, h/o prior cancer treatment, and other malignancies were excluded...
July 2018: Indian Journal of Radiology & Imaging
Gabrielle B Rocque, Courtney P Williams, Kelly M Kenzik, Bradford E Jackson, Andres Azuero, Karina I Halilova, Stacey A Ingram, Maria Pisu, Andres Forero, Smita Bhatia
BACKGROUND: The impact of National Comprehensive Cancer Network (NCCN) treatment guideline concordance on costs, health care utilization, and mortality for patients with breast cancer and secondary metastases is unknown. METHODS: From 2007 to 2013, women with early-stage breast cancer who received treatment for secondary metastases (n = 5651) were evaluated for first recorded systemic therapy concordance with NCCN guidelines within the Surveillance, Epidemiology, and End Results Program-Medicare linked database...
October 14, 2018: Cancer
Wenxiang Wang, Yuxia Gao, Jing Hai, Jing Yang, Shufeng Duan
Increasing evidence shows that cancer stem cells are responsible for drug resistance and relapse of tumors. In breast cancer, HER2 induces Herceptin resistance by inducing cancer stem cells. In this study, we explored the effect of HER2 on cancer stem cells induction and drug sensitivity of ovarian cancer cell lines. Firstly, we found that HER2 overexpression (HER2 OE) induced, while HER2 knockdown (HER2 KD) decreased CD44+/CD24- population. Consistently, HER2 expression was closely correlated with the sphere formation efficiency (SFE) of ovarian cancer cells...
October 12, 2018: Bioscience Reports
H Evin Gulbahce, Philip S Bernard, Erin K Weltzien, Rachel E Factor, Lawrence H Kushi, Bette J Caan, Carol Sweeney
BACKGROUND: Although the proportion of triple-negative breast cancers (TNBCs) diagnosed among older women is low, the number of TNBC cases is substantial because of the high incidence of breast cancer after the age of 65 years. The molecular features of TNBC in this age group have not been well described. METHODS: This study examined a population-based cohort of women with stage I to III TNBC diagnosed between the ages of 25 and 91 years with the PAM50 gene expression subtyping assay...
October 12, 2018: Cancer
Kholoud Arafat, Elham Al Kubaisy, Shahrazad Sulaiman, Sherif M Karam, Zeina Al Natour, Ahmed H Hassan, Samir Attoub
BACKGROUND/AIMS: Breast cancer is the most common cancer in women worldwide, and within this cancer type, triple-negative breast cancers have the worst prognosis. The identification of new genes associated with triple-negative breast cancer progression is crucial for developing more specific anti-cancer targeted therapies, which could lead to a better management of these patients. In this context, we have recently demonstrated that SMARCAD1, a DEAD/H box-containing helicase, is involved in breast cancer cell migration, invasion, and metastasis...
October 11, 2018: Cellular Physiology and Biochemistry
P Cottu, V D'Hondt, S Dureau, F Lerebours, I Desmoulins, P-E Heudel, F P Duhoux, C Levy, M-A Mouret-Reynier, F Dalenc, J-S Frenel, C Jouannaud, L Venat-Bouvet, S Nguyen, J-M Ferrero, J-L Canon, J Grenier, C Callens, D Gentien, J Lemonnier, A Vincent-Salomon, S Delaloge
Background: Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC. Patients and Methods: NeoPAL (UCBG10/4, NCT02400567) is a randomised, parallel, non-comparative phase II study. Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2...
October 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Xu Liang, Adrien Briaux, Véronique Becette, Camille Benoist, Anais Boulai, Walid Chemlali, Anne Schnitzler, Sylvain Baulande, Sofia Rivera, Marie-Ange Mouret-Reynier, Laurence Venat Bouvet, Thibaut De La Motte Rouge, Jérôme Lemonnier, Florence Lerebours, Céline Callens
BACKGROUND: Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with both response to NET and prognosis. METHODS: Gene expression profiling using RNA sequencing was performed in 86 pre-NET and post-NET tumor samples. Targeted next-generation sequencing of 91 candidate breast cancer-associated genes was performed on DNA samples from 89 patients...
October 11, 2018: Journal of Hematology & Oncology
Arunkumar Karthikayan, Sathasivam Sureshkumar, Dharanipragada Kadambari, Chellappa Vijayakumar
OBJECTIVE: This study was conducted to assess the serum 25-hydroxy (OH) vitamin D levels in patients with breast cancer compared to healthy controls and to identify its association with aggressive breast cancer phenotypes. MATERIALS AND METHODS: Serum 25-OH vitamin D levels of 78 breast cancer patients and 78 matched healthy controls were estimated using ELISA. The cases and controls were matched with respect to age, menopausal status, parity, weight, height and co-morbidities...
August 2018: Archives of Endocrinology and Metabolism
Emiliano Cocco, F Javier Carmona, Pedram Razavi, Helen H Won, Yanyan Cai, Valentina Rossi, Carmen Chan, James Cownie, Joanne Soong, Eneda Toska, Sophie G Shifman, Ivana Sarotto, Peter Savas, Michael J Wick, Kyriakos P Papadopoulos, Alyssa Moriarty, Richard E Cutler, Francesca Avogadri-Connors, Alshad S Lalani, Richard P Bryce, Sarat Chandarlapaty, David M Hyman, David B Solit, Valentina Boni, Sherene Loi, José Baselga, Michael F Berger, Filippo Montemurro, Maurizio Scaltriti
Mutations in ERBB2 , the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of "HER2-negative" (not ERBB2 amplified) tumors but are rare in "HER2-positive" ( ERBB2 amplified) breast cancer. We analyzed DNA-sequencing data from HER2-positive patients and used cell lines and a patient-derived xenograft model to test the consequence of HER2 mutations on the efficacy of anti-HER2 agents such as trastuzumab, lapatinib, and neratinib, an irreversible pan-EGFR inhibitor...
October 9, 2018: Science Signaling
Ines Stevic, Volkmar Müller, Karsten Weber, Peter A Fasching, Thomas Karn, Frederic Marmé, Christian Schem, Elmar Stickeler, Carsten Denkert, Marion van Mackelenbergh, Christoph Salat, Andreas Schneeweiss, Klaus Pantel, Sibylle Loibl, Michael Untch, Heidi Schwarzenbach
BACKGROUND: The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC). METHODS: First, miRNA expression profiles were determined in exosomes derived from the plasma of 15 TNBC patients before neoadjuvant therapy using a quantitative TaqMan real-time PCR-based microRNA array card containing 384 different miRNAs...
October 10, 2018: BMC Medicine
Ming Yuan He, Chloé Rancoule, Amel Rehailia-Blanchard, Sophie Espenel, Jane-Chloé Trone, Emilie Bernichon, Elodie Guillaume, Alexis Vallard, Nicolas Magné
Triple-negative breast cancer (TNBC) (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) is viewed as an aggressive subgroup of breast cancer. Treating patients with TNBC remains clinically challenging. It's now well established than radiation therapy is able to improve locoregional control in breast cancer patients both after breast conserving surgery or mastectomy, with positive impact in high-risk patients for long-term survival. Biologic characterization of breast tumor different subtypes, in particular the heterogeneous subtype of TNBC could permit to adapt the treatment plan...
November 2018: Critical Reviews in Oncology/hematology
I Blancas, E Aguirre, S Morales, M L Gonzálvez, S Servitja, N Díaz, S Del Barco, A Barnadas, M Margelí, I García Carbonero, A Llombart
PURPOSE: To evaluate the efficacy and safety of oral weekly vinorelbine 60 mg/m2 for metastatic breast cancer (MBC) in patients previously treated with anthracyclines or taxanes in routine clinical practice. MATERIALS AND METHODS: Fifty-five patients were enrolled in a prospective multicentre study conducted in Spain. Women ≥ 18 years of age with locally advanced breast cancer who were not candidates for surgical treatment with a radical intention or patients with stage IV disease, and who had received a prior taxane or anthracycline regimen were eligible for participation...
October 6, 2018: Clinical & Translational Oncology
Geoffrey Alan Watson, Oana Deac, Razia Aslam, Richard O'Dwyer, Antonia Tierney, Sue Sukor, John Kennedy
BACKGROUND: The cyclin-dependent kinase 4/6 inhibitor palbociclib has emerged as a novel therapeutic agent in metastatic breast cancer. Neutropenia is commonly observed, and thus stringent treatment guidelines regarding complete blood count (CBC) monitoring have been developed. The aim of this study was to provide a real-world experience of the toxicities associated with palbociclib therapy and to evaluate compliance with CBC monitoring. PATIENTS AND METHODS: We performed a retrospective single-center audit of hormone receptor-positive metastatic breast cancer patients treated with palbociclib over a 6-month period in an Irish tertiary referral hospital...
September 8, 2018: Clinical Breast Cancer
Yingying Shen, Wei Zhang, Jianghua Liu, Jun He, Renxian Cao, Xiguang Chen, Xiuda Peng, Haifan Xu, Qiang Zhao, Jing Zhong, Wenjun Ding, Xiaoyong Lei, Yuyang Jiang, Xuyu Zu
Triple-negative breast cancer (TNBC) is insensitive to endocrine therapy and targeted therapy to human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor (PR). New targets and new targeted therapeutic drugs for TNBC are desperately needed. The present study confirmed that DCC-2036 inhibited the proliferation, invasion, migration and epithelial-mesenchymal transition (EMT) of TNBC cells as well as induced apoptosis. Moreover, the antiproliferative activity of DCC-2036 was more efficient than that of most clinical drugs...
October 5, 2018: International Journal of Cancer. Journal International du Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"